{
    "title": "114_hr2921",
    "content": "The \"Patients First Act of 2015\" aims to intensify research for improved understanding and treatments of diseases, promote ethical stem cell research and human clinical trials, and encourage the derivation of pluripotent stem cell lines without creating or destroying human embryos. The \"Patients First Act of 2015\" promotes ethical stem cell research and human clinical trials, including the derivation of pluripotent stem cell lines without creating or destroying human embryos. SEC. 409K focuses on human stem cell research and therapy. The Secretary conducts research on stem cells for disease treatments, prioritizing those with clinical benefits for patients. Research must not involve creating or destroying human embryos or using stem cells inconsistent with established standards. The Secretary will issue final guidelines within 90 days to ensure that research supported under the section is consistent with established standards and prioritized for potential clinical benefit in human patients. The section outlines criteria for evidence of improvement in patients or FDA approval for human trials. Definitions include 'human embryo' and 'risk of injury'. The term 'risk of injury' refers to subjecting a human embryo to a greater risk of injury or death than allowed for research on fetuses in utero. The Secretary must prioritize human stem cell research in accordance with section 409K and submit annual reports to Congress on peer-reviewed research proposals. The Secretary must prioritize human stem cell research and submit annual reports to Congress on peer-reviewed research proposals that were not funded, along with explanations for why they did not receive funding. Additionally, biennial reports on stem cells are required under the Public Health Service Act."
}